-
-
-
-
-
-
-
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
-
-
-
-
-
-
-
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
-
-
-
-
-
-
-
Indivior Announces Q1 2025 Financial Results
-
-
-
-
-
-
-
Indivior (INDV) lowers guidance
-
-
-
-
-
-
-
Indivior Announces U.S. Food and Drug Administration Approval of OPVEEĀ® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
-
-
-
-
-
-
-
Indivior PLC to Acquire Opiant Pharmaceuticals
-
-
-
-
-
-
-
Indivior Takes Strategic Alignment Actions
-
1,217,291 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

